NAGE Niagen Bioscience, Inc.

Nasdaq Medicinal Chemicals & Botanical Products DE CIK: 0001386570
AI RATING
HOLD
62% Confidence

Investment Thesis

Niagen demonstrates strong revenue growth (29.9% YoY) and healthy gross margins (63.5%), supported by a fortress balance sheet with $66.5M cash and minimal debt. However, a critical concern emerges: operating cash flow is -$1.2M despite $6.3M net income, indicating potential earnings quality issues or working capital stress that demands immediate clarification.

Strengths

  • + Strong revenue growth at 29.9% YoY with $31.5M revenue base
  • + Excellent gross margin of 63.5% indicates pricing power and operational efficiency
  • + Fortress balance sheet with $66.5M cash, 0.12x debt-to-equity, and 4.61x current ratio
  • + Robust liquidity with 3.55x quick ratio and 68.5x interest coverage
  • + EPS growth of 81.8% YoY demonstrates bottom-line expansion

Risks

  • ! Critical red flag: negative operating cash flow (-$1.2M) vs. positive net income ($6.3M) suggests earnings quality concerns or significant working capital absorption
  • ! Negative free cash flow (-$1.3M FCF margin of -4.3%) despite profitability indicates cash generation problems
  • ! Underwhelming returns: 7.7% ROE and 5.5% ROA are modest given the strong balance sheet
  • ! Extremely low capital expenditure ($147K) suggests minimal reinvestment in growth or R&D capacity
  • ! Large disconnect between accounting profits and cash generation requires immediate disclosure review

Key Metrics to Watch

Financial Metrics

Revenue
31.5M
Net Income
6.3M
EPS (Diluted)
$0.07
Free Cash Flow
-1.3M
Total Assets
114.3M
Cash
66.5M

Profitability Ratios

Gross Margin 63.5%
Operating Margin 5.0%
Net Margin 20.1%
ROE 7.7%
ROA 5.5%
FCF Margin -4.3%

Balance Sheet & Liquidity

Current Ratio
4.61x
Quick Ratio
3.55x
Debt/Equity
0.12x
Debt/Assets
28.0%
Interest Coverage
68.52x
Long-term Debt
10.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T11:30:00.590259 | Data as of: 2026-03-31 | Powered by Claude AI